Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  Epigenomics AG    ECX   DE000A11QW50

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Epigenomics : Announces 2017 Second Quarter and Six Months Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/09/2017 | 09:44am CEST

09. August 2017

PDF

  • Reimbursement in the United States is a focus of the company as it will have the greatest impact upon commercial adoption of Epi proColon
  • The expected issuance of the convertible bond as agreed in the voluntary takeover offer will improve the financial position of the company with the addition of approximately EUR 6.5 million

Berlin (Germany) and Germantown, MD (U.S.A.), August 9, 2017 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced its financial results for the second quarter and the six months 2017 ending June 30.

'In the second quarter, the voluntary takeover offer for Epigenomics was in the focal point of our activities', said Greg Hamilton, CEO of Epigenomics AG. 'After the minimum acceptance threshold of the offer was missed, securing robust financing for Epigenomics remains our key priority in order to successfully commercialize our products and develop innovative cancer tests in the future.'

Q2/6M 2017 Financial Results

  • Total Q2 2017 revenue decreased to EUR 0.2 million (Q2 2016: EUR 1.3 million) and 6M 2017 revenue was at EUR 0.5 million (6M 2016: EUR 1.6 million). In the second quarter of the previous year, our joint U.S. commercialization partner Polymedco had initially stocked up on large inventories of Epi proColon following the product's FDA approval. This resulted in a relatively high revenue figure for the quarter. Order volume for 6M 2017 is lower due to the lack of Medicare reimbursement in the United States.
  • Adjusted for non-cash expenses related to phantom stock programs, EBITDA in Q2 2017 was at EUR -3.4 million (Q2 2016: EUR -3.5 million); adjusted EBITDA for 6M 2017 amounted to EUR -5.8 million (6M 2016: EUR -5.7 million). Net loss amounted to EUR 4.1 million in Q2 2017 compared to EUR 3.3 million in Q2 2016, and EUR 6.5 million for 6M 2017 (6M 2016: EUR 7.6 million).
  • Net loss per share for Q2 2017 rose to EUR 0.18 (Q2 2016: EUR 0.16) and decreased for 6M 2016 to EUR 0.28 (6M 2016: EUR 0.39).
  • Cash consumption (cash outflow from operating and investing activities) was EUR 4.7 million in 6M 2017 compared to EUR 4.3 million in 6M 2016.
  • Liquid assets (including marketable securities) amounted to EUR 7.7 million at the reporting date (December 31, 2016: EUR 3million).

Outlook for 2017

  • On July 6, 2017, after the end of the reporting period, we adjusted our outlook for the second half of the year. Due to the fact that revenue remained below expectations in the first half of 2017 (approximately EUR 0.5 million) and the fact that there would be most likely no Medicare reimbursement in the U.S. market over the remainder of the year, we now expect revenue to amount to between EUR 1.0 million and EUR 1.5 million in fiscal year 2017 (previously: approximately EUR 2.5 million).
  • Based on the reduced revenue forecast and due to potential additional costs, adjusted EBITDA (excluding expenses in relation to share-based payments) is now expected to range between EUR -12.5 million and EUR -14.0 million at the end of the year (previously: EUR -12.0 to EUR -13.5 million).
  • Given that acceptance of Summit Hero's takeover offer to the shareholders of our Company was insufficient, the Company now faces an uncertain situation with respect to its liquidity, as the available liquid funds as of June 30, 2017 are only expected to last until the first quarter of 2018 based on the current cash consumption. The planned issuance of convertible bonds to Cathay Fortune (CFIC) would provide additional cash in the amount of approximately EUR 6.5 million and extend cash reach to Q3/2018 (based on current cash consumption).
  • We will continue to carefully examine all available strategic options for securing the continued existence of the Company in this phase of uncertainty. These options explicitly include further capital market transactions aimed at procuring additional funds.

Further Information

The full interim statement on the financial results can be obtained from Epigenomics' website at: http://www.epigenomics.com/news-investors/financial-reports/

Conference call for analysts and investors

The Company will host a conference call and webcast at 4.00 pm CET / 10.00 am EDT, today. The presentation can be followed on the Company's website.

The dial-in numbers for the conference call are:

Germany: +49 30 232531411
UK: +44 203 7887007
USA: +1 312 4799416

A transcript of the conference call will be provided on Epigenomics' website subsequently: http://www.epigenomics.com/news-investors/financial-reports/.

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics' second product, Epi proLung®, is in development as a blood-based test for lung cancer detection.

For more information, visit www.epigenomics.com.

Contact:
Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: ir@epigenomics.com

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Epigenomics AG published this content on 09 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 09 August 2017 07:41:09 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EPIGENOMICS AG
08/09 EPIGENOMICS : Announces 2017 Second Quarter and Six Months Financial Results
08/09 DGAP-NEWS : Epigenomics AG Announces 2017 Second Quarter and Six Months Financia..
08/07 EPIGENOMICS AG : Notice of Loss pursuant to § 92 par. 1 AktG
08/07 DGAP-ADHOC : Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG
07/12 EPIGENOMICS AG : Voluntary public takeover offer by Summit Hero Holding not succ..
07/12 DGAP-NEWS : Epigenomics AG: Voluntary public takeover offer by Summit Hero Holdi..
07/07 EPIGENOMICS AG : Executive Board and Supervisory Board recommend acceptance of t..
07/07 EPIGENOMICS : Offer document published for the voluntary public takeover offer f..
07/07 EPIGENOMICS : issues change in guidance for financial year 2017
07/06 DGAP-ADHOC : Epigenomics AG issues change in guidance for financial year 2017
More news
News from SeekingAlpha
08/12 Epigenomics' (EPGNF) CEO Gregory Hamilton on Q2 2017 Results - Earnings Call ..
08/09 Epigenomics reports Q2 results
05/10 Epigenomics reports Q1 results
05/01 Epigenomics' (EPGNF) CEO Gregory Hamilton on Q4 2016 Results - Earnings Call ..
04/27 Epigenomics Goes Private
Financials (€)
Sales 2017 3,15 M
EBIT 2017 -13,4 M
Net income 2017 -13,9 M
Finance 2017 35,5 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 18,3x
EV / Sales 2018 3,28x
Capitalization 93,2 M
Chart EPIGENOMICS AG
Duration : Period :
Epigenomics AG Technical Analysis Chart | ECX | DE000A11QW50 | 4-Traders
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 6,11 €
Spread / Average Target 49%
EPS Revisions
Managers
NameTitle
Gregory K. Hamilton Chief Executive Officer
Heino von Prondzynski Chairman-Supervisory Board
Uwe Staub Chief Operating Officer
Günther Reiter Vice Chairman-Supervisory Board
Ann Clare Kessler Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
EPIGENOMICS AG-6.65%110
MIRACA HOLDINGS INC.-6.56%2 579
BEIJING STRONG BIOTECHNOLOGIES INC--.--%1 120
GENSCRIPT BIOTECH CORP17.30%954
INNATE PHARMA-27.99%710
SEEGENE INC--.--%674